Not Yet Recruiting
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent - CA239-0028
Mis à jour: 20 juillet, 2026 | ClinicalTrials.gov
Phase
Sexe(s)
Tranche d’âge
Emplacement(s)
Not Yet Recruiting
Inclusion Criteria: - Participants must be of Japanese descent (both biological parents of the participant are ethnically Japanese). - Participants must be healthy adult without clinically significant deviation from normal in medical history, PE, 12-lead ECG, vital sign measurements, and clinical laboratory assessments as determined by the investigator. - Participants must have Body mass index of 18.0 kg/m2 to 32.0 kg/m2. - Participants must have Total body weight ≥ 50 kg. Exclusion Criteria: - Participants must not have significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator. - Other protocol defined Inclusion/Exclusion criteria apply.
Nous vous recommandons fortement de contacter BMS pour signaler les effets secondaires (événements indésirables).
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici.
Signaler des effets secondaires (effets indésirables) ou des plaintes concernant la qualité du produit: Informations médicales
